Browsing Tag
European Commission
245 posts
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the…
April 25, 2024
European Commission approves Illumina’s divestment plan for GRAIL
The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed…
April 14, 2024
Arcturus Therapeutics’ ARCT-032 gets EU’s orphan medicinal product designation for cystic fibrosis
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading global clinical-stage messenger RNA medicines company, has achieved a significant…
February 22, 2024
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals,…
February 18, 2024
Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU
In a landmark decision, the European Commission (EC) has authorized Biogen Inc.’s SKYCLARYS (omaveloxolone) for the treatment of…
February 13, 2024
EC grants approval for GSK’s Omjjara for treatment of myelofibrosis patients with anaemia
In a landmark decision, the European Commission has approved GSK plc’s Omjjara (momelotinib), introducing a revolutionary treatment for…
February 5, 2024
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc.…
January 28, 2024
Adobe and Figma mutually terminate $20bn merger agreement
In a surprising turn of events, Adobe (Nasdaq:ADBE) and Figma announced the mutual termination of their previously announced…
December 18, 2023
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that…
December 9, 2023
Takeda’s TAKHZYRO approved by EC for pediatric hereditary angioedema
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission’s approval…
November 18, 2023